62. Paroxysmal nocturnal hemoglobinuria Clinical trials / Disease details


Clinical trials : 271 Drugs : 163 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 106

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-004438-39-ES
(EUCTR)
02/11/202123/07/2021BCX9930 treatment in patients with an inadequate response to C5 inhibitorsA Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Subjects with Inadequate Response to C5 Inhibitor Therapy - REDEEM 1 Paroxysmal Nocturnal Hemoglobinuria
MedDRA version: 21.1;Level: PT;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: BCX9930
Product Code: BCX9930
INN or Proposed INN: BCX9930
Other descriptive name: BCX9930 hydrochloride
Trade Name: Solaris
Product Name: eculizumab
Product Code: eculizumab
INN or Proposed INN: Eculizumab
Other descriptive name: Soliris
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: ravulizumab
INN or Proposed INN: RAVULIZUMAB
BioCryst Pharmaceuticals IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
81Phase 2United States;Taiwan;Spain;Turkey;Colombia;United Kingdom;France;Hungary;European Union;Canada;Argentina;Brazil;China;Japan;Korea, Republic of
2EUCTR2020-004438-39-HU
(EUCTR)
01/09/202102/07/2021BCX9930 treatment in patients with an inadequate response to C5 inhibitorsA Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Subjects with Inadequate Response to C5 Inhibitor Therapy - REDEEM 1 Paroxysmal Nocturnal Hemoglobinuria
MedDRA version: 21.1;Level: PT;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: BCX9930
Product Code: BCX9930
INN or Proposed INN: BCX9930
Other descriptive name: BCX9930 hydrochloride
Trade Name: Solaris
Product Name: eculizumab
Product Code: eculizumab
INN or Proposed INN: Eculizumab
Other descriptive name: Soliris
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: ravulizumab
INN or Proposed INN: RAVULIZUMAB
BioCryst Pharmaceuticals IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
81Phase 2United States;Taiwan;Spain;Turkey;Colombia;Italy;United Kingdom;France;Hungary;European Union;Canada;Argentina;Brazil;China;Japan;Korea, Republic of
3EUCTR2020-004438-39-FR
(EUCTR)
26/08/202116/06/2021BCX9930 treatment in patients with an inadequate response to C5 inhibitorsA Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Subjects with Inadequate Response to C5 Inhibitor Therapy - REDEEM 1 Paroxysmal Nocturnal Hemoglobinuria
MedDRA version: 21.1;Level: PT;Classification code 10034042;Term: Paroxysmal nocturnal haemoglobinuria;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: BCX9930
Product Code: BCX9930
INN or Proposed INN: BCX9930
Other descriptive name: BCX9930 hydrochloride
Trade Name: Solaris
Product Name: eculizumab
Product Code: eculizumab
INN or Proposed INN: Eculizumab
Other descriptive name: Soliris
Trade Name: Ultomiris
Product Name: Ravulizumab
Product Code: ravulizumab
INN or Proposed INN: RAVULIZUMAB
BioCryst Pharmaceuticals IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
81Phase 2United States;Taiwan;Turkey;Colombia;United Kingdom;France;Hungary;European Union;Canada;Argentina;Brazil;China;Japan;Korea, Republic of